Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma

BACKGROUND: Tivantinib has been described as a highly selective inhibitor of MET and is currently in a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC). However, the mechanism of tivantinib anti-tumor effect has been questioned by recent studies. RESULTS: We show that tiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Xiang, Qingfeng, Zhen, Zuojun, Deng, David YB, Wang, Jingnan, Chen, Yingjun, Li, Jieyuan, Zhang, Yingfei, Wang, Fengjie, Chen, Ningning, Chen, Huanwei, Chen, Yajin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603939/
https://ncbi.nlm.nih.gov/pubmed/26458953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-015-0238-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados